Stay updated with breaking news from Ming Yan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cytek Biosciences (NASDAQ:CTKB – Free Report) had its price objective trimmed by Morgan Stanley from $8.00 to $7.00 in a research report released on Thursday morning, Benzinga reports. The firm currently has an equal weight rating on the stock. Several other equities analysts have also commented on CTKB. Raymond James initiated coverage on Cytek Biosciences […]
The move reflects a similar trend globally where countries are stepping up their scrutiny of investments to protect critical industries. Read more at straitstimes.com.
On September 19, 2023, Ming Yan, the Chief Technology Officer (CTO) of Cytek Biosciences Inc (NASDAQ:CTKB), sold 20,000 shares of the company.
Hhlr Advisors LTD. reduced its stake in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB – Free Report) by 11.3% in the first quarter, according to its most recent filing with the SEC. The fund owned 7,703,514 shares of the company’s stock after selling 981,016 shares during the period. Cytek Biosciences makes up 1.3% of Hhlr Advisors […]
Protégé Ventures has launched Fund II to support startups led by student founders, while Cambridge Associates MD Ming Yan has relocated to Singapore.